Chordoma of the skull base: Predictors of tumor recurrence

Roberto Pallini, Giulio Maira, Francesco Pierconti, Maria Laura Falchetti, Ester Alvino, Graziella Cimino-Reale, Eduardo Fernandez, Ettore D'Ambrosio, Luigi Maria Larocca

Research output: Contribution to journalArticle

Abstract

Object. Chordomas of the skull base are generally regarded as slow-growing tumors; however, approximately 20% of these lesions have been shown to recur as early as 1 year postsurgery. The classic pathological paradigms are poor predictors of outcome, and additional markers are needed to identify patients at risk for early tumor recurrence. In this study the authors describe such a marker. Methods. In a series of 26 patients with chordomas of the skull base, the authors investigated the relationship between the biological behavior of the tumor, which was determined according to the interval for its recurrence and volume doubling time, and several pathological and molecular features, which included the histological variant, proliferative activity, mutation of p53 protein, expression of human telomerase reverse transcriptase (hTERT) messenger (m)RNA, loss of heterozygosity (LOH), and microsatellite instability. The major finding in this study was that hTERT mRNA expression in chordoma cells identifies those tumors that exhibit unusually fast rates of growth. The expression of hTERT mRNA was frequently associated with mutation of p53 protein, indicating that telomerase dysfunction combines with abnormal p53 function to initiate the unrestrained clonal expansion of the tumor cells. In cases in which the tumor was partially removed, mutation of p53 protein and expression of hTERT mRNA predicted increased doubling time for residual tumor as well as the probability of tumor recurrence. Cell proliferation, as investigated using the Ki-67 method, was significantly related to the tumor doubling time; however, the authors found that the pattern of cell proliferation was not homogeneous throughout the chordoma tissue, and that the proliferative index might change by a factor as high as 8 among different regions of the same tumor. The LOH and microsatellite instability do not seem to affect the prognosis of skull base chordomas. Conclusions. Reactivation of telomerase in chordomas is a reliable predictor of outcome. The ability to predict the biological behavior of chordomas might have immediate implications in the management of this disease in patients who undergo surgery.

Original languageEnglish
Pages (from-to)812-822
Number of pages11
JournalJournal of Neurosurgery
Volume98
Issue number4
Publication statusPublished - Apr 1 2003

Fingerprint

Chordoma
Skull Base
Recurrence
Neoplasms
Microsatellite Instability
Messenger RNA
Loss of Heterozygosity
Telomerase
Mutation
Cell Proliferation
Proteins
Residual Neoplasm
Disease Management

Keywords

  • Chordoma
  • Human telomerase reverse transcriptase
  • P53
  • Skull base
  • Tumor recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pallini, R., Maira, G., Pierconti, F., Falchetti, M. L., Alvino, E., Cimino-Reale, G., ... Larocca, L. M. (2003). Chordoma of the skull base: Predictors of tumor recurrence. Journal of Neurosurgery, 98(4), 812-822.

Chordoma of the skull base : Predictors of tumor recurrence. / Pallini, Roberto; Maira, Giulio; Pierconti, Francesco; Falchetti, Maria Laura; Alvino, Ester; Cimino-Reale, Graziella; Fernandez, Eduardo; D'Ambrosio, Ettore; Larocca, Luigi Maria.

In: Journal of Neurosurgery, Vol. 98, No. 4, 01.04.2003, p. 812-822.

Research output: Contribution to journalArticle

Pallini, R, Maira, G, Pierconti, F, Falchetti, ML, Alvino, E, Cimino-Reale, G, Fernandez, E, D'Ambrosio, E & Larocca, LM 2003, 'Chordoma of the skull base: Predictors of tumor recurrence', Journal of Neurosurgery, vol. 98, no. 4, pp. 812-822.
Pallini R, Maira G, Pierconti F, Falchetti ML, Alvino E, Cimino-Reale G et al. Chordoma of the skull base: Predictors of tumor recurrence. Journal of Neurosurgery. 2003 Apr 1;98(4):812-822.
Pallini, Roberto ; Maira, Giulio ; Pierconti, Francesco ; Falchetti, Maria Laura ; Alvino, Ester ; Cimino-Reale, Graziella ; Fernandez, Eduardo ; D'Ambrosio, Ettore ; Larocca, Luigi Maria. / Chordoma of the skull base : Predictors of tumor recurrence. In: Journal of Neurosurgery. 2003 ; Vol. 98, No. 4. pp. 812-822.
@article{99b5bc7cc0144eafbef66d9943bb40aa,
title = "Chordoma of the skull base: Predictors of tumor recurrence",
abstract = "Object. Chordomas of the skull base are generally regarded as slow-growing tumors; however, approximately 20{\%} of these lesions have been shown to recur as early as 1 year postsurgery. The classic pathological paradigms are poor predictors of outcome, and additional markers are needed to identify patients at risk for early tumor recurrence. In this study the authors describe such a marker. Methods. In a series of 26 patients with chordomas of the skull base, the authors investigated the relationship between the biological behavior of the tumor, which was determined according to the interval for its recurrence and volume doubling time, and several pathological and molecular features, which included the histological variant, proliferative activity, mutation of p53 protein, expression of human telomerase reverse transcriptase (hTERT) messenger (m)RNA, loss of heterozygosity (LOH), and microsatellite instability. The major finding in this study was that hTERT mRNA expression in chordoma cells identifies those tumors that exhibit unusually fast rates of growth. The expression of hTERT mRNA was frequently associated with mutation of p53 protein, indicating that telomerase dysfunction combines with abnormal p53 function to initiate the unrestrained clonal expansion of the tumor cells. In cases in which the tumor was partially removed, mutation of p53 protein and expression of hTERT mRNA predicted increased doubling time for residual tumor as well as the probability of tumor recurrence. Cell proliferation, as investigated using the Ki-67 method, was significantly related to the tumor doubling time; however, the authors found that the pattern of cell proliferation was not homogeneous throughout the chordoma tissue, and that the proliferative index might change by a factor as high as 8 among different regions of the same tumor. The LOH and microsatellite instability do not seem to affect the prognosis of skull base chordomas. Conclusions. Reactivation of telomerase in chordomas is a reliable predictor of outcome. The ability to predict the biological behavior of chordomas might have immediate implications in the management of this disease in patients who undergo surgery.",
keywords = "Chordoma, Human telomerase reverse transcriptase, P53, Skull base, Tumor recurrence",
author = "Roberto Pallini and Giulio Maira and Francesco Pierconti and Falchetti, {Maria Laura} and Ester Alvino and Graziella Cimino-Reale and Eduardo Fernandez and Ettore D'Ambrosio and Larocca, {Luigi Maria}",
year = "2003",
month = "4",
day = "1",
language = "English",
volume = "98",
pages = "812--822",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "4",

}

TY - JOUR

T1 - Chordoma of the skull base

T2 - Predictors of tumor recurrence

AU - Pallini, Roberto

AU - Maira, Giulio

AU - Pierconti, Francesco

AU - Falchetti, Maria Laura

AU - Alvino, Ester

AU - Cimino-Reale, Graziella

AU - Fernandez, Eduardo

AU - D'Ambrosio, Ettore

AU - Larocca, Luigi Maria

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Object. Chordomas of the skull base are generally regarded as slow-growing tumors; however, approximately 20% of these lesions have been shown to recur as early as 1 year postsurgery. The classic pathological paradigms are poor predictors of outcome, and additional markers are needed to identify patients at risk for early tumor recurrence. In this study the authors describe such a marker. Methods. In a series of 26 patients with chordomas of the skull base, the authors investigated the relationship between the biological behavior of the tumor, which was determined according to the interval for its recurrence and volume doubling time, and several pathological and molecular features, which included the histological variant, proliferative activity, mutation of p53 protein, expression of human telomerase reverse transcriptase (hTERT) messenger (m)RNA, loss of heterozygosity (LOH), and microsatellite instability. The major finding in this study was that hTERT mRNA expression in chordoma cells identifies those tumors that exhibit unusually fast rates of growth. The expression of hTERT mRNA was frequently associated with mutation of p53 protein, indicating that telomerase dysfunction combines with abnormal p53 function to initiate the unrestrained clonal expansion of the tumor cells. In cases in which the tumor was partially removed, mutation of p53 protein and expression of hTERT mRNA predicted increased doubling time for residual tumor as well as the probability of tumor recurrence. Cell proliferation, as investigated using the Ki-67 method, was significantly related to the tumor doubling time; however, the authors found that the pattern of cell proliferation was not homogeneous throughout the chordoma tissue, and that the proliferative index might change by a factor as high as 8 among different regions of the same tumor. The LOH and microsatellite instability do not seem to affect the prognosis of skull base chordomas. Conclusions. Reactivation of telomerase in chordomas is a reliable predictor of outcome. The ability to predict the biological behavior of chordomas might have immediate implications in the management of this disease in patients who undergo surgery.

AB - Object. Chordomas of the skull base are generally regarded as slow-growing tumors; however, approximately 20% of these lesions have been shown to recur as early as 1 year postsurgery. The classic pathological paradigms are poor predictors of outcome, and additional markers are needed to identify patients at risk for early tumor recurrence. In this study the authors describe such a marker. Methods. In a series of 26 patients with chordomas of the skull base, the authors investigated the relationship between the biological behavior of the tumor, which was determined according to the interval for its recurrence and volume doubling time, and several pathological and molecular features, which included the histological variant, proliferative activity, mutation of p53 protein, expression of human telomerase reverse transcriptase (hTERT) messenger (m)RNA, loss of heterozygosity (LOH), and microsatellite instability. The major finding in this study was that hTERT mRNA expression in chordoma cells identifies those tumors that exhibit unusually fast rates of growth. The expression of hTERT mRNA was frequently associated with mutation of p53 protein, indicating that telomerase dysfunction combines with abnormal p53 function to initiate the unrestrained clonal expansion of the tumor cells. In cases in which the tumor was partially removed, mutation of p53 protein and expression of hTERT mRNA predicted increased doubling time for residual tumor as well as the probability of tumor recurrence. Cell proliferation, as investigated using the Ki-67 method, was significantly related to the tumor doubling time; however, the authors found that the pattern of cell proliferation was not homogeneous throughout the chordoma tissue, and that the proliferative index might change by a factor as high as 8 among different regions of the same tumor. The LOH and microsatellite instability do not seem to affect the prognosis of skull base chordomas. Conclusions. Reactivation of telomerase in chordomas is a reliable predictor of outcome. The ability to predict the biological behavior of chordomas might have immediate implications in the management of this disease in patients who undergo surgery.

KW - Chordoma

KW - Human telomerase reverse transcriptase

KW - P53

KW - Skull base

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=0037381276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037381276&partnerID=8YFLogxK

M3 - Article

C2 - 12691407

AN - SCOPUS:0037381276

VL - 98

SP - 812

EP - 822

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 4

ER -